SB1 initiates coverage of Sobi with buy rating citing growth potential

SB1 analysts have initiated coverage of Swedish pharmaceutical firm Sobi, recommending a buy despite the stock trading at record highs. The recommendation is based on expectations of continued growth following a series of strong financial reports.